Appointment of the Biomedical Translation Fund Committee of Innovation Australia

Overview

The Industry Research and Development Act 1986 was enacted by the Parliament of Australia to address the need for enhanced support and facilitation of research and development activities across various industries, with a focus on fostering innovation. The Act aims to provide a framework that encourages and aids the development of research and innovation initiatives through the establishment of funds and committees dedicated to this purpose. The Act’s policy objective is to stimulate economic growth and competitiveness by supporting the translation of research into practical applications and commercial outcomes. The appointment of the Biomedical Translation Fund Committee of Innovation Australia under subsection 22(1) of the Act exemplifies the legislative intent to specifically address gaps in the conversion of biomedical research into tangible health benefits, thereby bridging the translational gap in the biomedical field.

Scope and Application

The Industry Research and Development Act 1986 applies to the establishment and operation of the Biomedical Translation Fund Committee of Innovation Australia, providing a legislative framework for research and development activities within the biomedical sector in Australia. This Act applies to the committee itself, which is tasked with offering advice on the Biomedical Translation Fund's operation and exercising any delegated functions or powers. The committee's jurisdiction extends nationally, aligning with the Commonwealth's legislative reach, thereby influencing biomedical research and development across the country. The Act does not explicitly state exclusions, exemptions, or thresholds within this particular appointment; however, the broader legislative context may encompass specific conditions and criteria for the committee's activities. The Act also allows for the extension or restriction of its application through subordinate instruments, thereby offering flexibility in managing the biomedical research and development landscape in Australia.

Key Provisions

The Industry Research and Development Act 1986 (the Act) appoints the Biomedical Translation Fund Committee of Innovation Australia under subsection 22(1) to provide advice and exercise delegated functions (subsection 22(1)(a) and (b)). This appointment is made by the Minister for Industry, Innovation and Science, in this instance Christopher Pyne. The Committee is tasked with advising on the operation of the Biomedical Translation Fund and can exercise any functions or powers delegated by the Board, as outlined in subsection 21(2) of the Act. The Act imposes several obligations on the Biomedical Translation Fund Committee. Firstly, it must provide expert advice on the operation of the Biomedical Translation Fund, ensuring that the fund is managed effectively and in line with its objectives. Additionally, the Committee is required to exercise any functions or powers delegated to it by the Board, which may include decision-making authority, oversight, and the implementation of specific initiatives related to the Biomedical Translation Fund. These responsibilities ensure that the fund is utilised efficiently and in alignment with the broader goals of promoting industry research and development. Failure to comply with the requirements and obligations set out in the Act could lead to various consequences. While the Act itself does not explicitly detail offences, penalties, or consequences for breach, breaches of statutory duties or mismanagement of funds could potentially lead to civil or criminal liability under other relevant laws. For instance, if the Committee fails in its duty to properly manage the Biomedical Translation Fund, it could face legal action for breaches of fiduciary duty or misapplication of funds. The penalties for such breaches would depend on the specific circumstances and the applicable laws at the time, but could include fines, restitution, or other civil or criminal penalties. It is important to note that while the Act does not specify maximum penalties, the overarching legal framework in Australia provides for a range of sanctions. For example, under general corporate and administrative law principles, penalties for breaches could include fines, imprisonment, or both. Additionally, individuals or entities found to have acted negligently or fraudulently in the management of the Biomedical Translation Fund could face personal liability. The precise consequences would be determined by the courts based on the nature and extent of the breach.